1. Home
  2. Studies
  3. ATBC

ATBC Study

ATBC logo
Datasets -
Variables -
Start Year
1984
Supplementary Information
The ATBC study was conducted by the Finnish Institute for Health and Welfare (THL) and the U.S. National Cancer Institute (NCI).
Visit ATBC

Members

Download
Investigators Contacts
  • PhD Satu Männistö
    Finnish Institute for Health and Welfare (THL)
  • PhD Satu Männistö
    Finnish Institute for Health and Welfare (THL)
  • Tuija Jääskeläinen
    Finnish Institute for Health and Welfare

Design

Study design
Cohort
Follow Up
The local data can be linked to Finnish National Health Registers (e.g., mortality, cancer, health care and medicines) through the Findata-process by request. Re-examinations of the participants have been done twice after the baseline.
Supplementary Information
Deaths and cardiovascular events are followed up for harmonized MORGAM data. See detailed information on the follow-up procedures used for MORGAM in the MORGAM e-publication.

Marker Paper

The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. Ann Epidemiol. 1994 Jan;4(1):1-10. doi: 10.1016/1047-2797(94)90036-1. PMID: 8205268.

Albanes D, Heinonen OP, Taylor PR, et al. Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. Journal of the National Cancer Institute, 1996; 88(21):1560-1570.

PUBMED 8205268

Recruitment

Sources of Recruitment
  • Individuals

Number of participants

Number of participants
29,133
Number of participants with biosamples
28,996
Supplementary Information
The ATBC study was a large, randomized, double-blind, placebo-controlled, 2x2 factorial primary prevention trial. Participating men were randomly assigned to four intervention groups: alpha-tocopherol alone, beta-carotene alone, both alpha-tocopherol and beta-carotene (total n=21846), and placebo group (n=7287).

Data Access

Availability of data and biosamples

Data
Biosamples
Other

Sector of research

Data Biosamples
Investigators from the public sector
Investigators from the private sector
Investigators from not-for-profit organization

Access can be granted to research plans that pursue high scientific quality and impact, and correspond with the research areas of THL Biobank. The research team should aim to publish the research results in peer-reviewed scientific journals shortly after the completion of the Project.

Transfer

Data Biosamples
Can leave the study facility
Can leave the country

Secure data access, such as passwords, firewalls, etc., must be in place to ensure that the shared data are kept secure.

Description of the access procedures

Biosamples and local data available are described in the THL Biobank webpage. Availability queries and application process to access THL Biobank resources are described in the application process page. The data of national health registers (e.g., mortality, cancer and other cases, health care and medicines) are available by request through Findata-process.

For access to the harmonized MORGAM data from many MORGAM Centres, one should seek a collaboration with any of the Centre which can submit a publication proposal to the MORGAM/BiomarCaRE Steering Group.


Availability of access information

On the study website : https://thl.fi/en/web/thl-biobank/for-researche...

By contacting the study representative

Yes
No
Not applicable
Don't know

Timeline

ATBC Study Cohort

Selection Criteria
Gender
men
Minimum age
50
Maximum age
69
Countries
  • Finland
Territory
Southern and western Finland
Ethnic Origin
Health Status
Other criteria
Smoker (smoking currently at least 5 cigarettes a day) and willing to participate in the ATBC Study (n=54171) were invited for further evaluation of their eligibility.
Supplementary Information
Exclusions were done due to a history of cancer or disease limiting long term participation, use of supplements of vitamins E and A and beta-carotene in excess of predefined dose, and treatment with anticoagulants.

Recruitment

Sources of recruitment
  • Specific population
Supplementary Information
Specific Population
  • Other specific population : Smoking men

Number of participants

Number of participants
29,133
Number of participants with biosamples
28,996
Supplementary Information
29133 men were randomly assigned to four intervention groups: alpha-tocopherol alone, beta-carotene alone, both alpha-tocopherol and beta-carotene, and placebo (n=7287). In the MORGAM data it is not possible to identify in which of the four intervention group the person belongs.
Data Collection Events
# Name Description Start End
0 ATBC Study Baseline Baseline examination during which participants completed a general risk factor, smoking, and medical history questionnaire, along with a food frequency questionnaire (FFQ). Background factors, ... 1984-12 1988-07
1 ATBC Study Round 2 Re-examinations of the cohort consisted of three annual visits to the local field center. Round 2 denotes the time of the intermediate serum sampling in a random sample of the cohort in the MORGAM ... 1986-08 1993-03
2 ATBC Study Round 3 Re-examinations of the cohort consisted of three annual visits to the local field center. Round 3 denotes the time of whole blood sampling in the MORGAM data. Participants were asked about their ... 1992-08 1993-04
3 ATBC Study Local mortality and disease outcome follow-up Local follow-up of the participants through registry linkage. The data of the Finnish national health registers (e.g., mortality, cancer, health care and medicines) can be linked for all ... 1984-12
4 ATBC Study Mortality and disease outcome follow-up in MORGAM data Follow-up for cardiovascular events and death in the harmonized MORGAM data, see more in [the MORGAM e-publication](https://www.thl.fi/publications/morgam/cohorts/full/finland/fin-atba.htm). For ... 1984-12 2004-12
# Name Description Size Actions
No files could be found.